[Clinical assessment of the radiotherapy and chemotherapy combined with cetuximabin in the treatment of nasopharyngeal carcinoma].

The aim of this study is toinvestigate the clinical effect of radiotherapy and chemotherapy combined with cetuximab in the treatment of nasopharyngeal carcinoma.Seventy-eight cases of nasopharyngeal carcinoma patients were divided into control group(n=42) and treatment group(n=36).The control group was treated with radiotherapy and diamminedichloroplatinum;the treatment group was treated with radiotherapy and diamminedichloroplatinum combined with cetuximab.Short-term efficacy,survival time,and adverse reactions were documented during following up in both groups.The efficiency in the treatment group (94.44%) was significantly higher than that in the control group(78.57%), <0.05.There were no significant difference of adverse reaction including radiodermatitis,oral mucosa reaction,bone marrow inhibition,radiation induced brain injury between the two groups, >0.05.The medium survival time of the treatment group(55 months) was significantly longer than that of the control group(48 months), <0.05.4-year survival rate in treatment group(88.89%) was significantly higher than that in the control group(69.05%), <0.05.4-year diseases free survival(DFS) rate in treatment group(75%) was significantly higher than that in the control group (59.52%), <0.05.Radiotherapy and chemotherapy combined with cetuximab can significantly improve the treatment efficiency in patients with nasopharyngeal carcinoma,while do not lead to higher rate of adverse reactions.This treatment is worth being promoted in clinical application.